Form 4: ATAI Life Sciences N.V. Reports Acquisition of Convertible Notes in IntelGenx Technologies Corp.

ATAI Life Sciences N.V. reports the acquisition of convertible notes in IntelGenx Technologies Corp. through a term loan provided by its subsidiary, ATAI AG.

Summary

• ATAI Life Sciences N.V. filed a Form 4 on May 3, 2024, regarding transactions in IntelGenx Technologies Corp. securities.
• On April 19, 2024, ATAI AG, a wholly-owned subsidiary of ATAI Life Sciences N.V., provided IntelGenx Corp. with an additional term loan of $1,000,000.
• This loan is convertible into shares of Common Stock at a price of $0.185 per share, potentially resulting in 5,405,405 shares.
• Accrued interest can also be converted into shares at a price based on the five-day volume-weighted average, less any applicable discount.
• The convertible notes expire on February 1, 2026.
• ATAI Life Sciences N.V. may be deemed to share beneficial ownership over these securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a financial transaction. The impact on IntelGenx depends on the market's view of the company's prospects and the terms of the loan.

Positives

• ATAI Life Sciences N.V. has increased its investment in IntelGenx Technologies Corp.
• The convertible notes provide a potential upside through equity conversion.

Risks

• The value of the convertible notes and underlying shares is subject to market fluctuations.
• The conversion of interest into shares could dilute existing shareholders.

Future Outlook

The document does not contain explicit forward-looking statements beyond the potential conversion of the loan and interest into IntelGenx shares.

Management Comments

• Florian Brand, Chief Executive Officer of ATAI Life Sciences N.V. and ATAI AG, signed the Form 4.

Industry Context

This investment reflects ATAI Life Sciences' continued interest in the pharmaceutical and drug delivery technology space, as IntelGenx Technologies Corp. specializes in innovative oral film technologies.

Comparison to Industry Standards

• Convertible notes are a common financing tool in the pharmaceutical industry, particularly for smaller companies seeking capital.
• The conversion price of $0.185 per share will be compared to the market price of IntelGenx shares to determine the value of the conversion option.
• Similar investments by venture capital and pharmaceutical companies can be compared to assess the terms and potential returns of this transaction.

Related Party Transactions

• The term loan from ATAI AG to IntelGenx Corp. is a related party transaction due to ATAI Life Sciences N.V.'s ownership stake in ATAI AG and its potential influence over IntelGenx as a 10% owner.

Stakeholder Impact

• Shareholders of IntelGenx may experience dilution if the convertible notes and interest are converted into shares.
• IntelGenx benefits from the additional capital provided by the term loan.
• ATAI Life Sciences N.V. increases its exposure to IntelGenx's performance.

Key Dates